MicroRNAs and Their Antagonists as Novel Therapeutics

Jeppe Vinther, Jakob Lewin Rukov, Noam Shomron*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


During the past decade, it has been realized that microRNAs (miRNAs) regulate expression of about half of human genes and thereby act as key mediators of most pathways involved in human health and disease. Given that miRNAs are often deregulated in disease processes, it comes as no surprise that therapeutic targeting of miRNA expression and function is a subject of intense investigation. Recently, the field has seen considerable progress, and the first miRNA drugs, in the form of miRNA antagonists, have entered clinical trials. In this chapter we will (1) explore how miRNAs function in health and how they change during disease development, focusing on the mode of miRNA regulation (often, this involves moderate control of many targets); (2) describe the strategies used to manipulate miRNA expression and the challenges associated in a clinical setting; (3) provide an overview of miRNAs and their antagonists as therapeutics; and (4) finally, discuss the therapeutic potential of miRNA manipulation and the caveats that come with it.

Original languageEnglish
Title of host publicationRNA Technologies
PublisherSpringer Science and Business Media Deutschland GmbH
Number of pages21
StatePublished - 2012

Publication series

NameRNA Technologies
ISSN (Print)2197-9731
ISSN (Electronic)2197-9758


  • MicroRNA
  • MicroRNA antagonism
  • MicroRNA delivery
  • RNA drugs
  • Therapeutics


Dive into the research topics of 'MicroRNAs and Their Antagonists as Novel Therapeutics'. Together they form a unique fingerprint.

Cite this